Published on 31 Jan 2024 on Simply Wall St. via Yahoo Finance
The past three years for Arbutus Biopharma (NASDAQ:ABUS) investors has not been profitable
Arbutus Biopharma Corporation (NASDAQ:ABUS) shareholders should be happy to see the share price up 25% in the last quarter. But that doesn't help the fact that the three year return is less impressive. Truth be told the share price declined 42% in three years and that return, Dear Reader, falls short of what you could have got from passive investing with an index fund.
Since shareholders are down over the longer term, lets look at the underlying fundamentals over the that time and see if they've been consistent with returns.
View our latest analysis for Arbutus Biopharma